Who was studied?
Adults with stable type 2 diabetes were assigned to placebo, 1 mg or 2 mg tesamorelin.
- Participants
- 53 adults in the published report
- Duration
- 12 weeks
- Funding
- Theratechnologies; author employment and consulting interests disclosed
What did the study find?
The trial found no significant between-group difference in its insulin-response endpoint or week-12 fasting glucose and HbA1c.
What should you keep in mind?
Small, short study focused on metabolic safety. It did not demonstrate equal visceral-fat reduction or superior tolerability with 1 mg. The registry lists 55 enrolled; the published report describes 53.
Why it matters
A dose comparison exists, but its endpoints do not validate the forum’s starter regimen or establish an absence of glucose risk over longer use.
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial
Published 2017 · PMID 28617838 · DOI 10.1371/journal.pone.0179538
Summary by Peptide Lit, checked against the original abstract on October 8, 2026. Read the complete paper for detailed methods and safety results. This page explains published research; it does not recommend a treatment or dose.